United States

Hikma Pharmaceuticals PLC (HIK.L)

HIK.L on London Stock Exchange

16 Jan 2017
Change (% chg)

3.00p (+0.16%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Select another date:

Tue, Nov 22 2016

BRIEF-Hikma announces U.S. deal with Vectura for generic salmeterol development

* Announces agreement with Vectura for development of generic salmeterol for U.S. market Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

BRIEF-Hikma Pharmaceuticals sees FY group revenue to grow by about 35 pct

* In US, good demand across a number of products and new product launches has more than offset increased competition for certain products

BUZZ-Hikma: top Stoxx loser as HSBC cuts TP on DoJ market probe

** Hikma Pharma -c.7% in heavy vols, biggest loser on Stoxx & trading at lowest in 10 mnths as HSBC cuts TP to 1985p from 2525p

BRIEF-Hikma says first-half revenue up 28 pct

* H1 group core operating profit of $176 mln, down 14 pct and down 3 pct in constant currency

BRIEF-Hikma sees FY revenue between $2-$2.1 bln

* Continue to expect group revenue to be in range of $2.0 bln to $2.1 bln for full year

BRIEF-Hikma says U.S. Court of Appeals upholds regulatory approval of colchicine

* Fda's regulatory approval of hikma's colchicine 0.6 mg capsule product was upheld.

BRIEF-Hikma Pharma announces U.S. launch of two generic tablets

* Announces launch of generic xeloda tablets 150 mg and 500 mg in US Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

Select another date: